About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 197 record(s)
Req # A-2021-000354
Adverse Drug Reaction (ADR) for AMLODIPINE BESILATE. Report number: E2B_03566994.Organization: Health Canada
February 2022
Req # A-2021-000359
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-103675-857.Organization: Health Canada
February 2022
Req # A-2021-000371
Adverse Drug Reactions (ADRs). Report numbers: 000938706, 000939911, E2B_03780743.Organization: Health Canada
February 2022
Req # A-2021-000428
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116090-508.Organization: Health Canada
February 2022
Req # A-2021-000478
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-114416-734.Organization: Health Canada
February 2022
Req # A-2021-000489
Adverse Drug Reactions (ADRs). Report numbers: 000940140, 000940217, E2B_03328955, E2B_03770785, E2B_03776338, E2B_03789132, E2B_03793285, E2B_03794891, E2B_03806231, E2B_03806721, E2B_03813468, E2B_03816471, E2B_03820452, E2B_03826853, E2B_03830060, E2B_03840580, E2B_03841049, E2B_03842140, 000939131, 000939482.Organization: Health Canada
February 2022
Req # A-2021-000641
Adverse Drug Reactions (ADRs). Report numbers: E2B_02741633, E2B_02862257, E2B_02897004, E2B_02963516, E2B_02965282, E2B_02742869, E2B_02984516, E2B_03070574, E2B_02991802, E2B_03001035, 000909256, E2B_03005526, E2B_03044333, E2B_03047640, E2B_02504349, E2B_02742893, E2B_02783825.Organization: Health Canada
February 2022
Req # A-2021-000834
Adverse Drug Reactions (ADRs) for RANITIDINE HYDROCHLORIDE. Report numbers: E2B_03504266, E2B_03497105, E2B_03444059, E2B_03473097.Organization: Health Canada
February 2022
Req # A-2021-000933
Adverse Drug Reactions (ADRs). Report numbers: E2B_04114262, E2B_04129068, E2B_04131597, E2B_04139146, E2B_04144833, E2B_04165428, E2B_04172465, E2B_04178373, E2B_04183810, E2B_04198702, E2B_04198707, E2B_04199333, E2B_04207023, E2B_04227694, 000958030, E2B_02764544, E2B_04219248, E2B_00114944, E2B_00320257, E2B_00263414.Organization: Health Canada
February 2022
Req # A-2021-000983
Adverse Drug Reactions (ADRs) for Abilify maintena. Report numbers: E2B_03858832, E2B_03865924, E2B_03847919, E2B_03851491, E2B_03851951, E2B_03852045, E2B_03868440, E2B_03950110, E2B_03982907, E2B_03996191. ADRs for Aripiprazole: E2B_03885413, E2B_03885517, E2B_03903766, E2B_03848354, E2B_03919693, E2B_03950595, E2B_03984215, E2B_04035487. ADRs for Brexpiprazole: E2B_04035487, E2B_04049742.Organization: Health Canada
February 2022